{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:41:11Z","timestamp":1781336471377,"version":"3.54.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The most crucial area to focus on when thinking of novel pathways for drug delivery into the CNS is the blood brain barrier (BBB). A number of nanoparticulate formulations have been shown in earlier research to target receptors at the BBB and transport therapeutics into the CNS. However, no mechanism for CNS entrance and movement throughout the CNS parenchyma has been proposed yet. Here, the truncated mini low-density lipoprotein receptor-related protein 1 mLRP1_DIV* was presented as blood to brain transport carrier, exemplified by antibodies and immunoliposomes using a systematic approach to screen the receptor and its ligands\u2019 route across endothelial cells <jats:italic>in vitro.<\/jats:italic><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The use of mLRP1_DIV* as liposomal carrier into the CNS was validated based on internalization and transport assays across an in vitro model of the BBB using hcMEC\/D3 and bEnd.3 cells. Trafficking routes of mLRP1_DIV* and corresponding cargo across endothelial cells were analyzed using immunofluorescence. Modulation of \u03b3-secretase activity by immunoliposomes loaded with the \u03b3-secretase modulator BB25 was investigated in co-cultures of bEnd.3 mLRP1_DIV* cells and CHO cells overexpressing human amyloid precursor protein (APP) and presenilin 1 (PSEN1).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We showed that while expressed in vitro, mLRP1_DIV* transports both, antibodies and functionalized immunoliposomes from luminal to basolateral side across an in vitro model of the BBB, followed by their mLRP1_DIV* dependent release of the cargo. Importantly, functionalized liposomes loaded with the \u03b3-secretase modulator BB25 were demonstrated to effectively reduce toxic A\u00df<jats:sub>42<\/jats:sub> peptide levels after mLRP1_DIV* mediated transport across a co-cultured endothelial monolayer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Together, the data strongly suggest mLRP1_DIV* as a promising tool for drug delivery into the CNS, as it allows a straight transport of cargo from luminal to abluminal side across an endothelial monolayer and it\u2019s release into brain parenchyma in vitro, where it exhibits its intended therapeutic effect.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12987-024-00573-1","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T13:28:11Z","timestamp":1726666091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-6368","authenticated-orcid":false,"given":"Laura","family":"Fritzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wienken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelia","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kurtyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"K\u00f6rbelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Weggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Fricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus U.","family":"Pietrzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"573_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/s0896-6273(02)01054-1","volume":"36","author":"WM Pardridge","year":"2002","unstructured":"Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron. 2002;36:555\u20138. https:\/\/doi.org\/10.1016\/s0896-6273(02)01054-1.","journal-title":"Neuron"},{"key":"573_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"NJ Abbott","year":"2006","unstructured":"Abbott NJ, R\u00f6nnb\u00e4ck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41\u201353. https:\/\/doi.org\/10.1038\/nrn1824.","journal-title":"Nat Rev Neurosci"},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","volume":"31","author":"B Engelhardt","year":"2009","unstructured":"Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol. 2009;31:497\u2013511. https:\/\/doi.org\/10.1007\/s00281-009-0177-0.","journal-title":"Semin Immunopathol"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1083\/jcb.34.1.207","volume":"34","author":"TS Reese","year":"1967","unstructured":"Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34:207\u201317. https:\/\/doi.org\/10.1083\/jcb.34.1.207.","journal-title":"J Cell Biol"},{"key":"573_CR5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1083\/jcb.40.3.648","volume":"40","author":"MW Brightman","year":"1969","unstructured":"Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969;40:648\u201377. https:\/\/doi.org\/10.1083\/jcb.40.3.648.","journal-title":"J Cell Biol"},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cne.901520103","volume":"152","author":"E Westergaard","year":"1973","unstructured":"Westergaard E, Brightman MW. Transport of proteins across normal cerebral arterioles. J Comp Neurol. 1973;152:17\u201344. https:\/\/doi.org\/10.1002\/cne.901520103.","journal-title":"J Comp Neurol"},{"key":"573_CR7","first-page":"600","volume":"60","author":"J Bernacki","year":"2008","unstructured":"Bernacki J, Dobrowolska A, Nierwi\u0144ska K, Ma\u0142ecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep. 2008;60:600\u201322.","journal-title":"Pharmacol Rep"},{"key":"573_CR8","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s11064-020-03030-1","volume":"45","author":"D Dwivedi","year":"2020","unstructured":"Dwivedi D, Megha K, Mishra R, Mandal PK. Glutathione in brain: overview of its conformations, functions, biochemical characteristics, quantitation and potential therapeutic role in Brain disorders. Neurochem Res. 2020;45:1461\u201380. https:\/\/doi.org\/10.1007\/s11064-020-03030-1.","journal-title":"Neurochem Res"},{"key":"573_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-3-319-96445-4_13","volume":"1097","author":"BM Fu","year":"2018","unstructured":"Fu BM. Transport across the blood-brain barrier. Adv Exp Med Biol. 2018;1097:235\u201359. https:\/\/doi.org\/10.1007\/978-3-319-96445-4_13.","journal-title":"Adv Exp Med Biol"},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","volume":"12","author":"WM Pardridge","year":"2007","unstructured":"Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12:54\u201361. https:\/\/doi.org\/10.1016\/j.drudis.2006.10.013.","journal-title":"Drug Discov Today"},{"key":"573_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3389\/fnins.2018.01019","volume":"12","author":"VM Pulgar","year":"2018","unstructured":"Pulgar VM. Transcytosis to Cross the blood brain barrier, New advancements and challenges. Front Neurosci. 2018;12:1019. https:\/\/doi.org\/10.3389\/fnins.2018.01019.","journal-title":"Front Neurosci"},{"key":"573_CR12","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.neurobiolaging.2015.06.028","volume":"36","author":"WD Brenowitz","year":"2015","unstructured":"Brenowitz WD, Nelson PT, Besser LM, Heller KB, Kukull WA. Cerebral amyloid angiopathy and its co-occurrence with Alzheimer\u2019s disease and other cerebrovascular neuropathologic changes. Neurobiol Aging. 2015;36:2702\u20138. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.06.028.","journal-title":"Neurobiol Aging"},{"key":"573_CR13","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1073\/pnas.0509386103","volume":"103","author":"J-P Guo","year":"2006","unstructured":"Guo J-P, Arai T, Miklossy J, McGeer PL. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2006;103:1953\u20138. https:\/\/doi.org\/10.1073\/pnas.0509386103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"272374","DOI":"10.1155\/2012\/272374","volume":"2012","author":"H Wang","year":"2012","unstructured":"Wang H, Megill A, He K, Kirkwood A, Lee H-K. Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity. Neural Plast. 2012;2012:272374. https:\/\/doi.org\/10.1155\/2012\/272374.","journal-title":"Neural Plast"},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/abt\/tbac028","volume":"5","author":"P Zhao","year":"2022","unstructured":"Zhao P, Zhang N, An Z. Engineering antibody and protein therapeutics to cross the blood-brain barrier. Antib Ther. 2022;5:311\u201331. https:\/\/doi.org\/10.1093\/abt\/tbac028.","journal-title":"Antib Ther"},{"key":"573_CR16","doi-asserted-by":"publisher","first-page":"11990","DOI":"10.1038\/srep11990","volume":"5","author":"X Tian","year":"2015","unstructured":"Tian X, Nyberg S, Sharp S, Madsen P, Daneshpour J, Armes N. LRP-1-mediated intracellular antibody delivery to the Central Nervous System. Sci Rep. 2015;5:11990. https:\/\/doi.org\/10.1038\/srep11990.","journal-title":"Sci Rep"},{"key":"573_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/JCI81108","volume":"126","author":"SE Storck","year":"2016","unstructured":"Storck SE, Meister S, Nahrath J, Mei\u00dfner JN, Schubert N, Di Spiezio A, et al. Endothelial LRP1 transports amyloid-\u03b2(1\u201342) across the blood-brain barrier. J Clin Invest. 2016;126:123\u201336. https:\/\/doi.org\/10.1172\/JCI81108.","journal-title":"J Clin Invest"},{"key":"573_CR18","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s11095-017-2267-3","volume":"34","author":"SE Storck","year":"2017","unstructured":"Storck SE, Pietrzik CU. Endothelial LRP1 - A potential target for the treatment of Alzheimer\u2019s Disease: theme: Drug Discovery, Development and Delivery in Alzheimer\u2019s Disease Guest Editor: Davide Brambilla. Pharm Res. 2017;34:2637\u201351. https:\/\/doi.org\/10.1007\/s11095-017-2267-3.","journal-title":"Pharm Res"},{"key":"573_CR19","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm HP, Schumacher V, Sch\u00e4fer M, Imhof-Jung S, Freskg\u00e5rd P-O, Brady K, et al. Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs. 2023;15:2261509. https:\/\/doi.org\/10.1080\/19420862.2023.2261509.","journal-title":"MAbs"},{"key":"573_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10354-016-0505-7","volume":"166","author":"M Nairz","year":"2016","unstructured":"Nairz M, Theurl I, Wolf D, Weiss G. Eisenmangel Oder Entz\u00fcndungsan\u00e4mie? Differenzialdiagnose und Mechanismen Der Entz\u00fcndungsan\u00e4mie. [Iron deficiency or anemia of inflammation? Differential diagnosis and mechanisms of anemia of inflammation]. Wien Med Wochenschr. 2016;166:411\u201323. https:\/\/doi.org\/10.1007\/s10354-016-0505-7.","journal-title":"Wien Med Wochenschr"},{"key":"573_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133\u201350. https:\/\/doi.org\/10.1038\/nrneurol.2017.188.","journal-title":"Nat Rev Neurol"},{"key":"573_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cell.2020.06.041","volume":"182","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Zlokovic BV. Therapeutic TVs for crossing barriers in the brain. Cell. 2020;182:267\u20139. https:\/\/doi.org\/10.1016\/j.cell.2020.06.041.","journal-title":"Cell"},{"key":"573_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.gendis.2021.12.011","volume":"10","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang Y, Liu J. Friend or foe for obesity: how hepatokines remodel adipose tissues and translational perspective. Genes Dis. 2023;10:825\u201347. https:\/\/doi.org\/10.1016\/j.gendis.2021.12.011.","journal-title":"Genes Dis"},{"key":"573_CR24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jconrel.2010.11.033","volume":"152","author":"JK Sahni","year":"2011","unstructured":"Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer\u2019s disease. J Control Release. 2011;152:208\u201331.","journal-title":"J Control Release"},{"key":"573_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1755-5949.2010.00199.x","volume":"17","author":"EF Craparo","year":"2011","unstructured":"Craparo EF, Bond\u00ec ML, Pitarresi G, Cavallaro G. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther. 2011;17:670\u20137. https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00199.x.","journal-title":"CNS Neurosci Ther"},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1749-6632.1986.tb27155.x","volume":"481","author":"SI Rapoport","year":"1986","unstructured":"Rapoport SI, Robinson PJ. Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann N Y Acad Sci. 1986;481:250\u201367. https:\/\/doi.org\/10.1111\/j.1749-6632.1986.tb27155.x.","journal-title":"Ann N Y Acad Sci"},{"key":"573_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1517\/17425247.5.2.155","volume":"5","author":"G Tosi","year":"2008","unstructured":"Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv. 2008;5:155\u201374. https:\/\/doi.org\/10.1517\/17425247.5.2.155.","journal-title":"Expert Opin Drug Deliv"},{"key":"573_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1749-6632.2009.05361.x","volume":"1199","author":"GA Silva","year":"2010","unstructured":"Silva GA. Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system. Ann N Y Acad Sci. 2010;1199:221\u201330. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.05361.x.","journal-title":"Ann N Y Acad Sci"},{"key":"573_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27041372","author":"P Liu","year":"2022","unstructured":"Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, Regulatory environments, and future perspectives. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27041372.","journal-title":"Molecules"},{"key":"573_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s0169-409x(99)00043-5","volume":"40","author":"E Mastrobattista","year":"1999","unstructured":"Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev. 1999;40:103\u201327. https:\/\/doi.org\/10.1016\/s0169-409x(99)00043-5.","journal-title":"Adv Drug Deliv Rev"},{"key":"573_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.seminoncol.2004.08.009","volume":"31","author":"JW Park","year":"2004","unstructured":"Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol. 2004;31:196\u2013205. https:\/\/doi.org\/10.1053\/j.seminoncol.2004.08.009.","journal-title":"Semin Oncol"},{"key":"573_CR32","unstructured":"Ghlichloo I, Gerriets V, StatPearls. Nonsteroidal anti-inflammatory drugs (NSAIDs). Treasure Island (FL); 2023."},{"key":"573_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1096\/fj.03-0645rev","volume":"18","author":"TD Warner","year":"2004","unstructured":"Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790\u2013804. https:\/\/doi.org\/10.1096\/fj.03-0645rev.","journal-title":"FASEB J"},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-0-387-71522-3_11","volume-title":"Pharmacological mechanisms in Alzheimer\u2019s therapeutics","author":"S Weggen","year":"2007","unstructured":"Weggen S, Czirr E, Leuchtenberger S, Eriksen J. Nonsteroidal anti-inflammatory drugs (NSAIDs) and derived A\u03b242-Lowering molecules for treatment and Prevention of Alzheimer\u2019s Disease (AD). In: Cuello AC, editor. Pharmacological mechanisms in Alzheimer\u2019s therapeutics. New York, NY: Springer New York; 2007. pp. 167\u201393. https:\/\/doi.org\/10.1007\/978-0-387-71522-3_11."},{"key":"573_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/alzrt225","volume":"5","author":"S Meister","year":"2013","unstructured":"Meister S, Zlatev I, Stab J, Docter D, Baches S, Stauber RH, et al. Nanoparticulate flurbiprofen reduces amyloid-\u03b242 generation in an in vitro blood-brain barrier model. Alzheimers Res Ther. 2013;5:51. https:\/\/doi.org\/10.1186\/alzrt225.","journal-title":"Alzheimers Res Ther"},{"key":"573_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.celrep.2012.11.028","volume":"3","author":"M Okochi","year":"2013","unstructured":"Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, Mori K, et al. \u03b3-secretase modulators and presenilin 1 mutants act differently on presenilin\/\u03b3-secretase function to cleave A\u03b242 and A\u03b243. Cell Rep. 2013;3:42\u201351. https:\/\/doi.org\/10.1016\/j.celrep.2012.11.028.","journal-title":"Cell Rep"},{"key":"573_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","volume":"184","author":"G Yang","year":"2021","unstructured":"Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y. Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs. Cell. 2021;184:521\u2013e53314. https:\/\/doi.org\/10.1016\/j.cell.2020.11.049.","journal-title":"Cell"},{"key":"573_CR38","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.2174\/138161206778793029","volume":"12","author":"S Leuchtenberger","year":"2006","unstructured":"Leuchtenberger S, Beher D, Weggen S. Selective modulation of Abeta42 production in Alzheimer\u2019s disease: non-steroidal anti-inflammatory drugs and beyond. Curr Pharm Des. 2006;12:4337\u201355. https:\/\/doi.org\/10.2174\/138161206778793029.","journal-title":"Curr Pharm Des"},{"key":"573_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1471-4159.2010.07118.x","volume":"116","author":"S Hahn","year":"2011","unstructured":"Hahn S, Br\u00fcning T, Ness J, Czirr E, Baches S, Gijsen H, et al. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer\u2019s disease attenuate the response of cultured cells to \u03b3-secretase modulators regardless of their potency and structure. J Neurochem. 2011;116:385\u201395. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.07118.x.","journal-title":"J Neurochem"},{"key":"573_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.15252\/emmm.201506078","volume":"8","author":"J K\u00f6rbelin","year":"2016","unstructured":"K\u00f6rbelin J, Dogbevia G, Michelfelder S, Ridder DA, Hunger A, Wenzel J, et al. A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol Med. 2016;8:609\u201325. https:\/\/doi.org\/10.15252\/emmm.201506078.","journal-title":"EMBO Mol Med"},{"key":"573_CR41","doi-asserted-by":"publisher","first-page":"31831","DOI":"10.1074\/jbc.M303592200","volume":"278","author":"S Weggen","year":"2003","unstructured":"Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem. 2003;278:31831\u20137. https:\/\/doi.org\/10.1074\/jbc.M303592200.","journal-title":"J Biol Chem"},{"key":"573_CR42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382. https:\/\/doi.org\/10.1038\/nmeth.2019.","journal-title":"Nat Methods"},{"key":"573_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature11087","volume":"485","author":"RD Bell","year":"2012","unstructured":"Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512\u20136. https:\/\/doi.org\/10.1038\/nature11087.","journal-title":"Nature"},{"key":"573_CR44","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41596-019-0212-0","volume":"14","author":"Y-K Lee","year":"2019","unstructured":"Lee Y-K, Uchida H, Smith H, Ito A, Sanchez T. The isolation and molecular characterization of cerebral microvessels. Nat Protoc. 2019;14:3059\u201381. https:\/\/doi.org\/10.1038\/s41596-019-0212-0.","journal-title":"Nat Protoc"},{"key":"573_CR45","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1007\/s12035-021-02421-x","volume":"58","author":"SC Christensen","year":"2021","unstructured":"Christensen SC, Hudecz D, Jensen A, Christensen S, Nielsen MS. Basigin antibodies with Capacity for Drug Delivery Across Brain endothelial cells. Mol Neurobiol. 2021;58:4392\u2013403. https:\/\/doi.org\/10.1007\/s12035-021-02421-x.","journal-title":"Mol Neurobiol"},{"key":"573_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1247\/csf.21043","volume":"46","author":"T Izumi","year":"2021","unstructured":"Izumi T. In vivo roles of Rab27 and its effectors in Exocytosis. Cell Struct Funct. 2021;46:79\u201394. https:\/\/doi.org\/10.1247\/csf.21043.","journal-title":"Cell Struct Funct"},{"key":"573_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1507\/endocrj.kr-78","volume":"54","author":"T Izumi","year":"2007","unstructured":"Izumi T. Physiological roles of Rab27 effectors in regulated exocytosis. Endocr J. 2007;54:649\u201357. https:\/\/doi.org\/10.1507\/endocrj.kr-78.","journal-title":"Endocr J"},{"key":"573_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41419-020-2709-4","volume":"11","author":"Y Feng","year":"2020","unstructured":"Feng Y, Zhong X, Tang T-T, Wang C, Wang L-T, Li Z-L, et al. Rab27a dependent exosome releasing participated in albumin handling as a coordinated approach to lysosome in kidney disease. Cell Death Dis. 2020;11:513. https:\/\/doi.org\/10.1038\/s41419-020-2709-4.","journal-title":"Cell Death Dis"},{"key":"573_CR49","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41380-022-01511-z","volume":"27","author":"EG Knox","year":"2022","unstructured":"Knox EG, Aburto MR, Clarke G, Cryan JF, O\u2019Driscoll CM. The blood-brain barrier in aging and neurodegeneration. Mol Psychiatry. 2022;27:2659\u201373. https:\/\/doi.org\/10.1038\/s41380-022-01511-z.","journal-title":"Mol Psychiatry"},{"key":"573_CR50","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1083\/jcb.129.1.203","volume":"129","author":"MG Lampugnani","year":"1995","unstructured":"Lampugnani MG, Corada M, Caveda L, Breviario F, Ayalon O, Geiger B, Dejana E. The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, beta-catenin, and alpha-catenin with vascular endothelial cadherin (VE-cadherin). J Cell Biol. 1995;129:203\u201317. https:\/\/doi.org\/10.1083\/jcb.129.1.203.","journal-title":"J Cell Biol"},{"key":"573_CR51","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","volume":"5","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al. The burden of neurological diseases in Europe: an analysis for the global burden of Disease Study 2017. Lancet Public Health. 2020;5:e551\u201367. https:\/\/doi.org\/10.1016\/S2468-2667(20)30190-0.","journal-title":"Lancet Public Health"},{"key":"573_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5582\/ddt.2015.01016","volume":"9","author":"J Gao","year":"2015","unstructured":"Gao J, Wang Z, Liu H, Wang L, Huang G. Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. Drug Discov Ther. 2015;9:205\u201312. https:\/\/doi.org\/10.5582\/ddt.2015.01016.","journal-title":"Drug Discov Ther"},{"key":"573_CR53","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.3390\/ijms15033612","volume":"15","author":"S Wu","year":"2014","unstructured":"Wu S, Li G, Li X, Lin C, Yu D, Luan S, Ma C. Transport of glial cell line-derived neurotrophic factor into liposomes across the blood-brain barrier: in vitro and in vivo studies. Int J Mol Sci. 2014;15:3612\u201323. https:\/\/doi.org\/10.3390\/ijms15033612.","journal-title":"Int J Mol Sci"},{"key":"573_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"A Akbarzadeh","year":"2013","unstructured":"Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102. https:\/\/doi.org\/10.1186\/1556-276X-8-102.","journal-title":"Nanoscale Res Lett"},{"key":"573_CR55","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1208\/s12248-021-00648-z","volume":"23","author":"F Juhairiyah","year":"2021","unstructured":"Juhairiyah F, de Lange ECM. Understanding drug delivery to the Brain using liposome-based strategies: studies that provide mechanistic insights are essential. AAPS J. 2021;23:114. https:\/\/doi.org\/10.1208\/s12248-021-00648-z.","journal-title":"AAPS J"},{"key":"573_CR56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.15171\/bi.2016.30","volume":"6","author":"J Barar","year":"2016","unstructured":"Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6:225\u201348. https:\/\/doi.org\/10.15171\/bi.2016.30.","journal-title":"Bioimpacts"},{"key":"573_CR57","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1080\/09205063.2017.1348739","volume":"28","author":"W Han","year":"2017","unstructured":"Han W, Yin G, Pu X, Chen X, Liao X, Huang Z. Glioma targeted delivery strategy of doxorubicin-loaded liposomes by dual-ligand modification. J Biomater Sci Polym Ed. 2017;28:1695\u2013712. https:\/\/doi.org\/10.1080\/09205063.2017.1348739.","journal-title":"J Biomater Sci Polym Ed"},{"key":"573_CR58","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0271678X17740031","volume":"38","author":"AS Haqqani","year":"2018","unstructured":"Haqqani AS, Delaney CE, Brunette E, Baumann E, Farrington GK, Sisk W, et al. Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier. J Cereb Blood Flow Metab. 2018;38:727\u201340. https:\/\/doi.org\/10.1177\/0271678X17740031.","journal-title":"J Cereb Blood Flow Metab"},{"key":"573_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/JAD-2011-101065","volume":"25","author":"A Haapasalo","year":"2011","unstructured":"Haapasalo A, Kovacs DM. The many substrates of presenilin\/\u03b3-secretase. J Alzheimers Dis. 2011;25:3\u201328. https:\/\/doi.org\/10.3233\/JAD-2011-101065.","journal-title":"J Alzheimers Dis"},{"key":"573_CR60","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","volume":"7","author":"GK Wilcock","year":"2008","unstructured":"Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer\u2019s disease: a randomised phase II trial. Lancet Neurol. 2008;7:483\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(08)70090-5.","journal-title":"Lancet Neurol"},{"key":"573_CR61","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557\u201364. https:\/\/doi.org\/10.1001\/jama.2009.1866.","journal-title":"JAMA"},{"key":"573_CR62","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/archneurol.2010.94","volume":"67","author":"M Sano","year":"2010","unstructured":"Sano M. Tarenflurbil: mechanisms and myths. Arch Neurol. 2010;67:750\u20132. https:\/\/doi.org\/10.1001\/archneurol.2010.94.","journal-title":"Arch Neurol"},{"key":"573_CR63","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.2147\/IJN.S239608","volume":"15","author":"L Kong","year":"2020","unstructured":"Kong L, Li X-T, Ni Y-N, Xiao H-H, Yao Y-J, Wang Y-Y, et al. Transferrin-modified Osthole PEGylated liposomes Travel the blood-brain barrier and mitigate Alzheimer\u2019s Disease-Related Pathology in APP\/PS-1 mice. Int J Nanomed. 2020;15:2841\u201358. https:\/\/doi.org\/10.2147\/IJN.S239608.","journal-title":"Int J Nanomed"},{"key":"573_CR64","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","volume":"367","author":"B Singh","year":"2024","unstructured":"Singh B, Day CM, Abdella S, Garg S. Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release. 2024;367:402\u201324. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.047.","journal-title":"J Control Release"},{"key":"573_CR65","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1126\/science.adj9255","volume":"382","author":"TE Golde","year":"2023","unstructured":"Golde TE, Levey AI. Immunotherapies for Alzheimer\u2019s disease. Science. 2023;382:1242\u20134. https:\/\/doi.org\/10.1126\/science.adj9255.","journal-title":"Science"},{"key":"573_CR66","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13024-023-00667-8","volume":"18","author":"KE Foley","year":"2023","unstructured":"Foley KE, Weekman EM, Wilcock DM. Mechanisms of ARIA: is it time to focus on the unique immune environment of the neurovascular unit? Mol Neurodegener. 2023;18:76. https:\/\/doi.org\/10.1186\/s13024-023-00667-8.","journal-title":"Mol Neurodegener"},{"key":"573_CR67","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","volume":"26","author":"T-Y Yang","year":"2022","unstructured":"Yang T-Y, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, et al. Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther Methods Clin Dev. 2022;26:471\u201394. https:\/\/doi.org\/10.1016\/j.omtm.2022.07.018.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"573_CR68","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/4743","volume":"5","author":"RW Herzog","year":"1999","unstructured":"Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56\u201363. https:\/\/doi.org\/10.1038\/4743.","journal-title":"Nat Med"},{"key":"573_CR69","doi-asserted-by":"publisher","first-page":"103658","DOI":"10.1016\/j.cellimm.2017.05.006","volume":"342","author":"RW Herzog","year":"2019","unstructured":"Herzog RW. Complexity of immune responses to AAV transgene products - example of factor IX. Cell Immunol. 2019;342:103658. https:\/\/doi.org\/10.1016\/j.cellimm.2017.05.006.","journal-title":"Cell Immunol"},{"key":"573_CR70","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N Engl J Med. 2010;363:1429\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1000228.","journal-title":"N Engl J Med"},{"key":"573_CR71","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1073\/pnas.1617726114","volume":"114","author":"R Calcedo","year":"2017","unstructured":"Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, et al. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for \u03b1-1-antitrypsin deficiency. Proc Natl Acad Sci U S A. 2017;114:1655\u20139. https:\/\/doi.org\/10.1073\/pnas.1617726114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"573_CR72","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143780","author":"M Muhuri","year":"2021","unstructured":"Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PW, Gao G. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI143780.","journal-title":"J Clin Invest"},{"key":"573_CR73","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","volume":"9","author":"Z Fitzpatrick","year":"2018","unstructured":"Fitzpatrick Z, Leborgne C, Barbon E, Masat E, Ronzitti G, van Wittenberghe L, et al. Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV Vector Transduction. Mol Ther Methods Clin Dev. 2018;9:119\u201329. https:\/\/doi.org\/10.1016\/j.omtm.2018.02.003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"573_CR74","doi-asserted-by":"publisher","unstructured":"Polaka S, Katrajkar K, Siva Reddy DV, Shukla H, Arafat B, Tekade RK. Factors affecting the pharmacokinetics of the liposomal drugs. In: Biopharmaceutics and Pharmacokinetics Considerations: Elsevier; 2021. pp. 567\u2013599. https:\/\/doi.org\/10.1016\/B978-0-12-814425-1.00016-4","DOI":"10.1016\/B978-0-12-814425-1.00016-4"},{"key":"573_CR75","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","volume":"3","author":"M Mehta","year":"2023","unstructured":"Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-based nanoparticles for Drug\/Gene delivery: an overview of the production techniques and difficulties encountered in their Industrial Development. ACS Mater Au. 2023;3:600\u201319. https:\/\/doi.org\/10.1021\/acsmaterialsau.3c00032.","journal-title":"ACS Mater Au"},{"key":"573_CR76","doi-asserted-by":"publisher","first-page":"e09394","DOI":"10.1016\/j.heliyon.2022.e09394","volume":"8","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8:e09394. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09394.","journal-title":"Heliyon"},{"key":"573_CR77","doi-asserted-by":"publisher","first-page":"101509","DOI":"10.1016\/j.jddst.2020.101509","volume":"56","author":"PP Mehta","year":"2020","unstructured":"Mehta PP, Ghoshal D, Pawar AP, Kadam SS, Dhapte-Pawar VS. Recent advances in inhalable liposomes for treatment of pulmonary diseases: Concept to clinical stance. J Drug Deliv Sci Technol. 2020;56:101509. https:\/\/doi.org\/10.1016\/j.jddst.2020.101509.","journal-title":"J Drug Deliv Sci Technol"},{"key":"573_CR78","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.survophthal.2004.12.006","volume":"50","author":"S Ebrahim","year":"2005","unstructured":"Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol. 2005;50:167\u201382. https:\/\/doi.org\/10.1016\/j.survophthal.2004.12.006.","journal-title":"Surv Ophthalmol"},{"key":"573_CR79","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00403-011-1166-4","volume":"303","author":"MBR Pierre","year":"2011","unstructured":"Pierre MBR, Dos Santos Miranda Costa I. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res. 2011;303:607\u201321. https:\/\/doi.org\/10.1007\/s00403-011-1166-4.","journal-title":"Arch Dermatol Res"},{"key":"573_CR80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.apsb.2018.06.005","volume":"9","author":"H He","year":"2019","unstructured":"He H, Lu Y, Qi J, Zhu Q, Chen Z, Wu W. Adapting liposomes for oral drug delivery. Acta Pharm Sin B. 2019;9:36\u201348. https:\/\/doi.org\/10.1016\/j.apsb.2018.06.005.","journal-title":"Acta Pharm Sin B"},{"key":"573_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/anbr.202100109","author":"L Xu","year":"2022","unstructured":"Xu L, Wang X, Liu Y, Yang G, Falconer RJ, Zhao C-X. Lipid nanoparticles for drug delivery. Adv NanoBiomed Res. 2022. https:\/\/doi.org\/10.1002\/anbr.202100109.","journal-title":"Adv NanoBiomed Res"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-024-00573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-024-00573-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-024-00573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:03:00Z","timestamp":1726718580000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-024-00573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1186\/s12987-024-00573-1","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were conducted in compliance with European and German guidelines for the care and use of laboratory animals and were approved by the Central Animal Facility of the University of Mainz and the ethical committee on animal care and use of Rhineland-Palatinate, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}